Breast Cancer Radiation Clinical Trial
Official title:
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
| Verified date | April 2024 |
| Source | Dana-Farber Cancer Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
| Status | Active, not recruiting |
| Enrollment | 671 |
| Est. completion date | June 2026 |
| Est. primary completion date | December 2025 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 50 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Histologically confirmed invasive breast cancer - The primary tumor must be excised via breast conserving surgery ("lumpectomy") with negative margins ("no ink on tumor") or re-excision showing no residual disease in the re-excision specimen. - The tumor must be =2 cm (T1) in the largest dimension. - Immunohistochemical studies must demonstrate the tumor to be ER+ (=10%) or PR+, HER2- and grade 1 or 2. - The patient must have undergone either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) demonstrating pathologic node-negativity (pN0). However, patients with immunohistochemical evidence of isolated tumor cells in a lymph node [pN0(i+)] are eligible if no deposit >0.2mm is identified. - Age: this study is open to patients between 50 and 75 years of age (inclusive). Patients younger than 50 years of age are excluded based on prior data suggesting a different natural history for breast cancers arising in premenopausal women (with different subtype and biologic distributions that may confound the current aims). Women older than 75 years of age are excluded from this protocol due to historical difficulties achieving robust follow-up in this population, along with competing comorbidities which have been shown to interfere with subsequent breast cancer monitoring and evaluation. - ECOG performance status =2 (Karnofsky =60%) - Life expectancy of >5 years per the clinical impression of the treating physician(s). - Eligible for and willing to undergo a course of adjuvant endocrine therapy. Exclusion Criteria: - At the time of enrollment, subjects may not have had any prior systemic therapy for breast cancer, including chemotherapy, hormonal therapy or targeted biologic therapy. Similarly, chemotherapy or biologic therapy must not be part of the subsequent treatment plan. - Clinical, radiographic or pathologic evidence of multicentric disease. - Evidence of T4 disease (e.g., involvement of the chest wall, skin, dermal lymphatics, or inflammatory breast cancer). - Grade 3 histology. - Tumors in which the invasive component is present only as micro-invasion. - Multicentric invasive or in site carcinoma - Bilateral breast malignancy. - Inability or unwillingness to tolerate endocrine therapy. - Documented mutation of TP53, BRCA1, BRCA2, or other hereditary cancer syndromes. - Significant comorbidity associated with an estimation of <5 remaining life years. - Another diagnosis of malignancy within the 5 years preceding enrollment (excluding non-melanoma skin cancers or in situ cervical lesions, which are permitted). - Inability to understand or provide informed consent. - Current addictive or psychiatric disorder which may preclude protocol adherence. - Prior breast or chest radiotherapy for any indication. - Pregnant or lactating. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Johns Hopkins | Baltimore | Maryland |
| United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
| United States | Massachusetts General Hospital | Boston | Massachusetts |
| United States | Memorial Sloane Kettering Cancer Center | New York | New York |
| United States | NYU Langone Health | New York | New York |
| United States | Lifespan Cancer Institute | Providence | Rhode Island |
| Lead Sponsor | Collaborator |
|---|---|
| Dana-Farber Cancer Institute | NanoString Technologies, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Five-Year Risk of Local Regional Recurrence in the Ipsilateral Breast or Lymph Nodes in Women without Adjuvant Radiotherapy | Using information gathered from follow-up physical examinations and mammography, the 5-year risk of local regional recurrence in women who omit radiotherapy post-lumpectomy will be evaluated. | 5 years | |
| Secondary | Five-Year Risk of Any Recurrence: Local, Regional or Distant | Using information gathered from follow-up physical examinations and mammography, the 5-year risk of any recurrence in women who omit radiotherapy post-lumpectomy will be evaluated. | 5 years | |
| Secondary | Overall Survival | Using information gathered from follow-up appointments and other record sources, 5-year survival rates will be evaluated. | 5 years | |
| Secondary | Disease-Free Survival | Using information gathered from follow-up physical exams, mammography and other imaging as necessary, the rate of disease-free status at 5 years will be evaluated. | 5 years |